Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Company leadership, know this: We long-time longs trust you have, over these long months, consulted and planned with top-drawer experts on how to roll out the good news in a way that maximizes attention from the scientific community, the investment world and big pharma. Another slip-shod bamboozle like May 10th's (already a footnote in your legacy) must not occur.
Good summary, Doc. Thanks for your continued sharing of knowledge and expertise. Happy holiday!
Doc, as you know I'm very long. Even longer after today's relatively small purchase.
Further dialogue with Dave Innes:
He: "We are required to have an ASM and we are currently constrained with regard to any formal TLD announcement because we are actively pursuing a journal publication."
Me: "Are you able to describe the status of that pursuit, e.g., that it's totally in the hands of a publication, or is still undergoing peer review or final edits, etc.? Thank you."
He: "Unfortunately, I cannot. Sorry I can’t be of more help. "
Via email, after Dave Innes told me there's no date yet for the annual shareholders meeting, I pressed him on whether we at least know the location and whether it will be "in-person" or just a webcast. His response: "Not yet. Depends on covid issues at the time."
Can I have July 16th, please?
Okay. I'll reach for a Hamilton.
At this point, Doc, would you accept a Jefferson?
Surprised there's so little conversation here about today's MRK biotech story on page 1 of the WS Journal...
Doc: My aging heart (now nearly eight years older than when I first bought NWBO) always steadies itself when you remind us of forgotten or ignored facts. In just one chamber, however, lurks a noesis that management should have been able to better anticipate certain possibilities that led to last month's price meltdown. Then, perhaps, this community's waters would now be smoother and we'd be at a higher level from which to gather new capital or sprint toward a partnership or buyout. I'm much longer than I ever expected to be...at roughly a break-even point--if you don't count what the investment could have produced elsewhere. I'm pretty sure I'll continue to hang on...hoping we reach the dock before the heart stops beating.
Agree with everything you say, Doc, except this: Smart sodbusters make sure their tools are sharp so they can be as productive/efficient as possible when conditions permit progress. I wish I could feel certain the NWBO team has planned well.
Well done, Danish Dude!
And I'm still waiting for the New Zealand results from Synthetec (nzym)! :)
Having some six dozen authors, all of whom I presume must sign off on any significant edit, surely complicates things. But any day now...
I essentially asked that question in an email to investor relations three days ago. Still no response...just the automatic reply saying, "Thank you...we'll get back to you soon."
I must acknowledge that NWBO's definition of "soon" has always been substantially different from mine.
From today's NY Times:
Breast Cancer Drug Trial Results in
'Unheard-of' Survival Rates
The patients had metastatic breast cancer that had been progressing despite rounds of harsh chemotherapy. But a treatment with a drug that targeted cancer cells with laserlike precision was stunningly successful, slowing tumor growth and extending life to an extent rarely seen with advanced cancers.
The new study, presented at the annual meeting of the American Society of Clinical Oncology and published on Sunday in the New England Journal of Medicine, would change how medicine was practiced, cancer specialists said.
“This is a new standard of care,” said Dr. Eric Winer, a breast cancer specialist, director of the Yale Cancer Center and head of the A.S.C.O. Dr. Winer was not involved with the study. He added that “it affects a huge number of patients.”
FYI two days ago I emailed an inquiry to investor relations, asking whether the company can at least confirm that publication issues have now left the company's hands and are now in the purview of a scientific/medical journal. I have received no response.
A phase 2 study gets prominent attention from NY Times:
A drug trial unexpectedly obliterated rectal cancer in every single patient.
A small study of patients with rectal cancer yielded an astonishing result: All of the participants completed the trial with their cancer being undetectable by any kind of exam or scan. None of them had significant side effects. “I believe this is the first time this has happened in the history of cancer,” one of the study’s authors said.
The patients in the study took a drug called dostarlimab, which unmasked cancer cells and allowed the immune system to identify and destroy them. The research will need to be replicated, and it’s unclear how long remission will last.
Think we'll see $1+ tomorrow...
I predict the medical journal story will precede the annual meeting by less than a month, that the annual meeting will occur by mid-August, and that significant general media attention will occur shortly after the peer-reviewed medical journal story.
And as long as I'm in forecast mode, let me also say I anticipate the share price will approach $5 by the annual meeting.
Ready to pounce on any mis-step. Like an "a" instead of an "an."
I'll drink one unsweet iced tea to that!
Heart rate has returned to normal, Doc. Thank you. And BTW, I bought a substantial chunk at 66.5 cents today, increasing my holdings by 8 percent..
You're my trusted NWBO barometer, Doc. That I read a little doubt between your lines...should it worry me?
From today's (6/1) New York Times: Researchers have managed to tame pancreatic cancer in a woman whose cancer was far advanced and after other forms of treatment had failed. The experiment that helped her is complex and highly personalized and is not immediately applicable to most cancer patients. Another pancreatic cancer patient, who received the same treatment, did not respond and died of her disease.
Nonetheless, a leading journal — The New England Journal of Medicine — published a report of the study on Wednesday.
Dr. Eric Rubin, the journal’s editor in chief called the proof of concept experiment “an important step along the way” to devising similar treatments that might be applicable to lung, colon and other cancers.
The experiment involved genetically reprogramming the patient’s T cells, a type of white blood cell of the immune system, so they can recognize and kill cancer cells.
Actually, what he says could very possibly be true, and if NWBO is handling it properly, it probably is.
I, too, have a media and PR background, have actually worked "exclusives" with major outlets. It's not unusual to give a major outlet exclusive rights to a story with a confidentiality agreement that it must be held until an agreed-on date, giving the media outlet time to prepare a deeply-researched story that can be told with proper context.
(In my best personal example, NBC Dateline did an hour on my subject one night and the story was on page 1 of "USA Today" the next morning. One had exclusive broadcast rights; the other exclusive print rights.
If this science is as good as we think and hope it will be, this very well could be a major story in the NY Times or WS Journal...or to give the USA-based shorts a morning headache, maybe the story breaks first in a major European publication and the U.S. media (and shorts) have to play cover. Here's hoping...
I predict almost all of those "no's" will become "yes" in the next 40 days.
I'm sure Adam read your recent posting (and is reading this one, too)--and I hope yours brings him a restless night/week/summer.
And probably is reading this board hourly to feed his withering ego.
Dr. Lisa Coussens is AACR's current president. Her phone number:
503-494-9336
No disagreement with your overall sentiment. However, as a seven-year and now holder of a significant amount of NWBO, I believe that from a communications perspective, the company has done a very poor job of protecting stockholder value. Done right, this stock should have held $2 with the revelation from last week's conference. Instead we have to build from 65 cents--my average price over seven years. That money could have been used elsewhere over seven years.
Excellent move.
Doc Logic: Thoughts on this, please?
"Sharkee, the 5.7% GBM survivors are mostly from the era before IDH1 mutations were identified and therefore are not currently classified as GBM. I am an oncologist and have never had a GBM survivor (have treated over 1000) before TTF and DCVax with > 5 year survival. Those that survived longer were in the controls are almost certainly not what we call GBM now."
Who's buying NWBO today? Probably the scientists who were at Tuesday's presentation. Meanwhile the NWBO communications strategy for this rollout can serve as a MBA casebook study on how not to introduce scientific study results, gain proper investor and media community respect and avoid market manipulation.
Grade "A" for the science. Grade "D-" for the communication strategy. Hope someone holds some feet to the fire at the annual shareholders meeting.
Been looking for more perspective from you today, Doc. Needed a little calm in the storm.
All probably true--but it still reflects a very poor communications strategy. Presentation at a science conference should have occurred after (shortly after or nearly simultaneous) to publication in a science journal and a PR release...not the other way around where the company is curtailed on what it can say or do.
The shorts had their way today and who knows how many tens of millions of shares big pharma purchased at less than $1 per share?
Congratulations to the scientists who have pursued what appears to be a remarkable advance in treatment of a terrible cancer. A Bronx cheer to management for the way it has handled communications. Again.
$NWBO data great. Managing to that constant
— Michael Bigger (@biggercapital) May 10, 2022
A Twitter quote from a person purportedly present for today's presentation:
"The Oncologists in the room were amazed. The guy next to me actually gasped."
Exactly right.
I would suggest today's "roll-out" was something less than a "public announcement."